Clinical Trial Update: Safety and Feasibility of ADRCs (Adipose Derived Regenerative Cells) in Patients With Grade II Hamstring Tears [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial investigating the safety and feasibility of adipose-derived regenerative cells (ADRCs) for Grade II hamstring injuries has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hamstring Injury

Drugs mentioned

• ADRCs (Adipose-Derived Regenerative Cells) (Adipose-Derived Regenerative Cells)

Snippet

Sponsor: Cytori Therapeutics | Conditions: Muscle Tear | Phase 1, Phase 2 | Status: WITHDRAWN